In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
There are several reasons why Celgene should buy Biogen.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.
A merger would be smart, profitable ... and attention-grabbing.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.